Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density.

ABSTRACT

Aim: Although Proton pump inhibitors (PPIs) are well-tolerated, their long-term use may be associated with decreased bone mass. Methods: This is a case-control study including patients treated with PPIs (>1 year) and control subjects who have not received PPIs treatment. Results: A total of 90 patients and 90 matched controls were included. PPIs use was associated with hypocalcemia and hypomagnesemia. Vitamin D3 deficiency and hyperparathyroidism were associated with PPIs use. Long-term PPIs use was significantly associated with decreased bone density. Risk factors of decreased bone mineral density (BMD) included age >50 years, menopause, lack of sun exposure, double PPIs dose, daily intake, post-meal intake and association with a mucoprotective agent. Conclusion: Our results highlight the risk of decreased BMD in patients on long-term PPIs treatment.

In this study, we investigated the impact of long-term use of proton pump inhibitors (PPIs) on bone health. Examining 90 patients on PPIs for over a year and matching them with control subjects, we found that PPIs were linked to lower bone density. Factors such as age over 50. menopause, limited sun exposure, higher PPIs dosage, daily intake, post-meal usage and combining PPIs with a mucoprotective agent were associated with decreased bone mineral density. Our findings emphasize the concern of reduced bone density in individuals undergoing prolonged PPIs treatment.